Selected References:

  • Ben-Horin S, et al. 2010. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol;8:475-6.
  • Burmester GR, et al. 2017. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 76(2):414-417.
  • Carter JD, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. The Journal of Rheumatology 36:3.
  • Carter JD, Valeriano J, Vasey FB. 2006. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33(5):1014-7.
  • Chambers CD, et al. 2019. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS One 14 (10).
  • Clark DA. 2010. Anti-TNFalpha therapy in immune-mediated subfertility: state of the art. J Reprod Immunol. 85(1):15-24.
  • Diav-Citrin O, et al. 2014. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study. Reprod Toxicol; 43: 78-84.
  • Fritzsche J, et al. 2012. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol; 46:718-9.
  • Johansen CB, et al. 2018. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: A review. Int J Mol Sci. 19(5):1349.
  • Julsgaard M, et al. 2013. Adalimumab levels in an infant. J Crohns Colitis;7(7):597-8.
  • Leung Y, et al. 2014. Management of the pregnant inflammatory bowel disease patient on anti-tumor necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol; 28(9):505-9.
  • Lund T, et al. 2016. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Derm Therapy. 30 (3).
  • Mahadevan U, et al. 2019. Inflammatory bowel disease in pregnancy clicinal care pathway: A report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology 156:1508-1524.
  • Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 155:696-704.
  • Micu MC, et al. 2014. TNF-alpha inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford). Jul;53(7):1250-5.
  • Mishkin DS, etal. 2006. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis. 12:827-828.
  • Picardo S, et al. 2019. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: Biologic and oral small molecule therapy. Drugs 79:1053-1063.
  • Ramonda R, et al. 2014. Influence of tumor necrosis factor alpha inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril; 101(2):359-65.
  • Roux CH, et al. 2006. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{alpha} therapy. Rheumatology 46:695-698.
  • Schnitzler F et al. 2011. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 17(9):1846-54.
  • Villiger PM, et al. 2010. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10): 1842-4.
  • Viktil KK, Engeland A, and Furu K. 2012. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scandinavian Journal of Rheumatology, 41( 3): 196-201
  • Weber-Schoendorfer C, et al. 2015. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol.
  • Winger EE et al., 2011. Birth defect rates in women using adalimumab (Humira®) to treat immunologic-based infertility in IVF patients. Am J Reprod Immunol. 66(3):237-41.